Turing Pharmaceuticals, which took a PR and financial beating after plans to exponentially raise the price of one of its drugs, has hired Washington help.Turing on Sept. 29 brought in lobbying and law firm Buchanan Ingersoll & Rooney for "strategy development" and to implement a government relations program.
The New York Times ignitied a firestorm around Turing last month, covering the 5,000 percent price increase of its drug Daraprim from $13 to $750. Chief communications officer Craig Rothenberg, a Johnson & Johnson alum, exited the company amid the crisis, which saw the company retreat on the planned price hike.
The flap has raised eyebrows in Washington and tossed around in the presidential primary season, as well.
Edward Allera, a managing parnter of K-street based BI&R, is co-chair of the firm's Food and Drug Administration section and is a former associate chief counsel of the FDA.
Ripp Media is supporting Turing on the PR front.
Charlie Chapman, a policy advisor to Health & Human Services Secretary Robert Kennedy Jr., has joined BGR’s health & life sciences practice.
The future of DTC should foster understanding and trust, as well as improving clinical conversations.
Healing the Sick Care System: Why People Matter, a new book from FINN Partners chair global health and purpose Gil Bashe, says that the current healthcare system is not broken because it lacks innovation, talent or investment, but because it has lost sight of the people it exists to serve.
